Inhibitory effects of Kampo medicine on human UGT2B7 activity

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 6, 2009, Pages 490-499

  Nakagawa, Nao ^a   Katoh, Miki ^a,b   Yoshioka, Yuko ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Drug interactions; Human liver microsomes; Inhibition; Kampo medicine; UGT

Indexed keywords

GLUCURONOSYLTRANSFERASE 2B7; KAMPO; MORPHINE; ZIDOVUDINE;

ARTICLE; CINNAMON; DRUG CONJUGATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCURONIDATION; GLYCYRRHIZA; INTESTINE; LIVER; MICROSOME; NONHUMAN; PLANT ROOT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RHIZOMA RHEI; RHUBARB;

EID: 73349092459     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.490     Document Type: Article

References (37)

1. Yu, F., Takahashi, T., Moriya, J., Kawaura, K., Yamakawa, J., Kusaka, K., Itoh, T., Morimoto, S., Yamaguchi, N. and Kanda, T.: Traditional Chinese medicine and Kampo: a review from the distant past for the future. J. Int. Med. Res., 34: 231-239 (2006).
2. Liu, K. H., Kim, M. J., Jeon, B. H., Shon, J. H., Cha, I. J., Cho, K. H., Lee, S. S. and Shin, J. G.: Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J. Clin. Pharm. Ther., 31: 83-91 (2006).
3. Ishizaki, T., Sasaki, F., Ameshima, S., Shiozaki, K., Takahashi, H., Abe, Y., Ito, S., Kuriyama, M., Nakai, T. and Kitagawa, M.: Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur. Respir. J., 9: 2691-2696 (1996).
4. Mori, K., Kondo, T., Kamiyama, Y., Kano, Y. and Tominaga, K.: Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 51: 403-406 (2003).
5. Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B. and Arlett, P.: St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol., 54: 349-356 (2002).
6. Takahashi, K., Uejima, E., Morisaki, T., Takahashi, K., Kurokawa, N. and Azuma, J.: In vitro inhibitory effects of Kampo medicines on metabolic reactions catalyzed by human liver microsomes. J. Clin. Pharm. Ther., 28: 319-327 (2003).
7. Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J. O., Owens, I. S. and Nebert, D. W.: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 15: 677-685 (2005).
8. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32: 1201-1208 (2004).
9. Coffman, B. L., Rios, G. R., King, C. D. and Tephly, T. R.: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos., 25: 1-4 (1997).
10. Radominska-Pandya, A., Little, J. M. and Czernik, P. J.: Human UDP-glucuronosyltransferase 2B7. Curr. Drug Metab., 2: 283-298 (2001).
11. Katoh, M., Yoshioka, Y., Nakagawa, N. and Yokoi, T.: Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. Drug Metab. Pharmacokinet., 24: 226-234 (2009).
12. Hibino, T., Yuzurihara, M., Terawaki, K., Kanno, H., Kase, Y. and Takeda, A.: Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. J. Pharmacol. Sci., 108: 89-94 (2008).
13. Shiratani, H., Katoh, M., Nakajima, M. and Yokoi, T.: Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab. Dispos., 36: 1745-1752 (2008).
14. Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., Von Moltke, L. L. and Greenblatt, D. J.: Evaluation of 3′- azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos., 31: 1125-1133 (2003).
15. Coffman, B. L., King, C. D., Rios, G. R. and Tephly, T. R.: The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos., 26: 73-77 (1998).
16. Engtrakul, J. J., Foti, R. S., Strelevitz, T. J. and Fisher, M. B.: Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab. Dispos., 33: 1621-1627 (2005).
17. Ashby, M., Fleming, B., Wood, M. and Somogyi, A.: Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J. Pain Symptom Manage., 14: 157-167 (1997).
18. Lee, B. L., Tauber, M. G., Sadler, B., Goldstein, D. and Chambers, H. F.: Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin. Pharmacol. Ther., 59: 14-21 (1996).
19. Foti, R. S., Wahlstrom, J. L. and Wienkers, L. C.: The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab. Dispos., 35: 185-188 (2007).
20. Stone, A. N., Mackenzie, P. I., Galetin, A., Houston, J. B. and Miners, J. O.: Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos., 31: 1086-1089 (2003).
21. Takeda, S., Kitajima, Y., Ishii, Y., Nishimura, Y., Mackenzie, P. I., Oguri, K. and Yamada, H.: Inhibition of UDP glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab. Dispos., 34: 1277-1282 (2006).
22. Sampol, E., Lacarelle, B., Rajaonarison, J. F., Catalin, J. and Durand, A.: Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br. J. Clin. Pharmacol., 40: 83-86 (1995).
23. Uchaipichat, V., Galetin, A., Houston, J. B., Mackenzie, P. I., Williams, J. A. and Miners, J. O.: Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol. Pharmacol., 74: 1152-1162 (2008).
24. Milne, R. W., Nation, R. L. and Somogyi, A. A.: The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev., 28: 345-472 (1996).
25. Hara, Y., Nakajima, M., Miyamoto, K. and Yokoi, T.: Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab. Pharmacokinet., 22: 103-112 (2007).
26. Pacifici, G. M., Gustafsson, L. L., Saä we, J. and Rane, A.: Metabolic interaction between morphine and various benzodiazepines. Acta. Pharmacol. Toxicol., 58: 249-252 (1986).
27. Tighe, K. E., Webb, A. M. and Hobbs, G. J.: Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: potential for opioid-related toxicity. Anesth. Analg., 88: 1137-1142 (1999).
28. Ventafridda, V., Bianchi, M., Ripamonti, C., Sacerdote, P., De Conno, F., Zecca, E. and Panerai, A. E.: Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain, 43: 155-162 (1990).
29. Nakamura, T., Sakai, A., Isogami, I., Noda, K., Ueno, K. and Yano, S.: Abatement of morphine-induced slowing in gastrointestinal transit by Dai-kenchu-to, a traditional Japanese herbal medicine. Jpn. J. Pharmacol., 88: 217-221 (2002).
30. Abraham, N. G., Bucher, D., Niranjan, U, Brown, A. C., Lutton, J. D., Distenfeld, A., Ahmed, T. and Levere, R. D.: Microenvironmental toxicity of azidothymidine: partial sparing with hemin. Blood, 74: 139-144 (1989).
31. Sahai, J., Gallicano, K., Pakuts, A. and Cameron, D. W.: Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis., 169: 1103-1107 (1994).
32. Trapnell, C. B., Klecker, R. W., Jamis-Dow, C. and Collins, J. M.: Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother., 42: 1592-1596 (1998).
33. Uchaipichat, V., Winner, L. K., Mackenzie, P. I., Elliot, D. J., Williams, J. A. and Miners, J. O.: Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol., 61: 427-439 (2006).
34. Rowland, A., Gaganis, P., Elliot, D. J., Mackenzie, P. I., Knights, K. M. and Miners, J. O.: Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol. Exp. Ther., 321: 137-147 (2007).
35. Yokoi, T., Narita, M., Nagai, E., Hagiwara, H., Aburada, M. and Kamataki, T.: Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn. J. Cancer Res., 86: 985-989 (1995).
36. Nakajima, M., Sakata, N., Ohashi, N., Kume, T. and Yokoi, T.: Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4′-hydroxyphenyl)-5-pheny lhydantoin in human liver microsomes. Drug Metab. Dispos., 30: 1250-1256 (2002).
37. Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A. and Hollenberg, P. F.: Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 32: 587-594 (2004).